ACADIA Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Catherine Owen Adams

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	9.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Catherine Owen Adams (54 yo)

less than a year

Görev süresi

Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. Ms. Owen Adams served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She se...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Schneyer	Executive VP & CFO	3.3yrs	US$2.59m	0.032% $ 1.0m
Stephen Davis	Consultant	less than a year	US$7.59m	0.11% $ 3.6m
Catherine Owen Adams	CEO & Director	less than a year	Veri yok	Veri yok
James Kihara	VP, Chief Accounting Officer & Corporate Controller	4.4yrs	Veri yok	0.012% $ 379.1k
Elizabeth Thompson	Executive VP and Head of Research & Development	less than a year	Veri yok	Veri yok
Benir Ruano	Senior Vice President of Technical Development	2.2yrs	Veri yok	Veri yok
Albert Kildani	Senior Vice President of Investor Relations & Corporate Communications	1.3yrs	Veri yok	Veri yok
Jennifer Rhodes	Executive VP	1yr	Veri yok	Veri yok
Rob Ackles	Senior VP & Chief People Officer	3yrs	Veri yok	Veri yok
Bob Mischler	Senior Vice President of New Product Planning & Strategy	no data	Veri yok	Veri yok
Ponni Subbiah	SVP, Global Head of Medical Affairs & Chief Medical Officer	5.2yrs	Veri yok	Veri yok
Julie Fisher	Senior Vice President of European Commercialization	1yr	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: 0A4W 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Catherine Owen Adams	CEO & Director	less than a year	Veri yok	Veri yok
Laura Brege	Independent Director	16.7yrs	US$392.75k	0.012% $ 384.5k
Julian Baker	Independent Director	9.1yrs	US$377.75k	0.062% $ 2.0m
Paul Anderson	Member of the Scientific and Clinical Advisory Board	no data	Veri yok	Veri yok
Edmund Harrigan	Independent Director	9.2yrs	US$387.75k	0.015% $ 489.5k
Daniel Soland	Independent Director	9.8yrs	US$387.75k	0.021% $ 661.3k
Arvid Carlsson	Member of the Scientific and Clinical Advisory Board	no data	Veri yok	Veri yok
Carol Tamminga	Member of the Scientific and Clinical Advisory Board	no data	Veri yok	Veri yok
Herbert Meltzer	Member of the Scientific and Clinical Advisory Board	no data	Veri yok	Veri yok
James Daly	Independent Director	9yrs	US$387.75k	0.015% $ 470.5k
Stephen Biggar	Independent Chairman of the Board	12yrs	US$432.75k	0.062% $ 2.0m
Elizabeth Garofalo	Independent Director	4.3yrs	US$377.75k	0.014% $ 429.5k

9.1yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0A4W 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/24 18:19
Gün Sonu Hisse Fiyatı	2025/01/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

ACADIA Pharmaceuticals Inc. 36 Bu analistlerden 18, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Joel Beatty	Baird
Ishan Majumdar	Baptista Research
Esther Lannie Hong	Berenberg

ACADIA Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Acadia Pharmaceuticals Inc. Appoints Thomas Garner as Chief Commercial Officer

ACADIA Pharmaceuticals Inc., Annual General Meeting, May 29, 2024

ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Acadia Pharmaceuticals Inc. Announces Executive Changes

Acadia Pharmaceuticals Inc. Announces Management Changes

Doug Williamson to Leave ACADIA Pharmaceuticals Inc. as Executive Vice President, Head of Research and Development

Recent updates

Acadia Pharmaceuticals Inc. Provides Sales Guidance for Full Year 2025

Acadia Pharmaceuticals Inc. Appoints Thomas Garner as Chief Commercial Officer

Third quarter 2024 earnings released: EPS: US$0.20 (vs US$0.40 loss in 3Q 2023)

ACADIA Pharmaceuticals Inc. Revises Earnings Guidance for the Year 2024

ACADIA Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 06, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.20 (vs US$0.007 in 2Q 2023)

ACADIA Pharmaceuticals Inc. Revises Earnings Guidance for the Full Year of 2024

ACADIA Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 06, 2024

Acadia Pharmaceuticals Inc. Announces the Journal Med Published Results from Two Open-Label Extension Studies, LILAC-1 and LILAC-2

ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.10 (vs US$0.27 loss in 1Q 2023)

ACADIA Pharmaceuticals Inc., Annual General Meeting, May 29, 2024

ACADIA Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024

Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting

ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

ACADIA Pharmaceuticals Inc. Provides Sales Guidance for the Full Year 2024

Full year 2023 earnings released: US$374 loss per share (vs US$1.34 loss in FY 2022)

ACADIA Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 27, 2024

Acadia Pharmaceuticals Inc. Announces Executive Changes

Acadia Pharmaceuticals Inc. Announces Management Changes

Acadia Pharmaceuticals Inc. Initiates Pivotal Phase 3 Study of Carbetocin (Acp-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome

Acadia Pharmaceuticals Inc. Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis

Acadia Pharmaceuticals Inc. Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis

Doug Williamson to Leave ACADIA Pharmaceuticals Inc. as Executive Vice President, Head of Research and Development

ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Third quarter 2023 earnings released: US$0.40 loss per share (vs US$0.17 loss in 3Q 2022)

ACADIA Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 02, 2023

Insufficient new directors

Acadia Pharmaceuticals Inc. Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals, Inc and Encourages Long-Term Acad Investors to Contact the Firm

Second quarter 2023 earnings released: EPS: US$0.007 (vs US$0.21 loss in 2Q 2022)

Acadia Pharmaceuticals Inc. Appoints Kevin R. Oliver as Senior Vice President, Chief Business Officer and Member of Executive Management Committee

ACADIA Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 02, 2023

New minor risk - Share price stability

ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Second Quarter and Third Quarter of 2023

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (Intranasal Carbetocin) for Prader-Willi Syndrome

Nature Medicine Publishes Results from Pivotal Phase 3 Largender Study Evaluating Daybue (trofinetide) Efficacy and Safety in Patients with Rett Syndrome

Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.70 loss in 1Q 2022)

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Full year 2022 earnings released: US$1.34 loss per share (vs US$1.05 loss in FY 2021)

ACADIA Pharmaceuticals Inc. to Report Q4, 2022 Results on Feb 27, 2023

ACADIA Pharmaceuticals Inc. Announces Executive Changes

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

Acadia Pharmaceuticals Inc. Provides Sales Guidance for the Full Year of 2022

Acadia Pharmaceuticals Inc. Announces Retirement of Srdjan (Serge) Stankovic as President

ACADIA Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 02, 2022

Acadia Pharmaceuticals Inc Appoints Adora Ndu to Its Board of Directors

ACADIA Pharmaceuticals Inc. Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA

No longer forecast to breakeven

ACADIA Pharmaceuticals Inc. Provides Sales Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.27 loss in 2Q 2021)

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

ACADIA Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 08, 2022

Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline

First quarter 2022 earnings released: US$0.70 loss per share (vs US$0.41 loss in 1Q 2021)

Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for Nuplazid

Insufficient new directors

ACADIA Pharmaceuticals Inc., Annual General Meeting, Jun 07, 2022

ACADIA Pharmaceuticals Inc. to Report Q1, 2022 Results on May 04, 2022

Acadia Pharmaceuticals Inc. Announces Top-Line Results from Phase 2 Study Evaluating Acp-044 for the Treatment of Acute Postoperative Pain

Full year 2021 earnings: Revenues and EPS in line with analyst expectations